Navigation Links
EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
Date:12/10/2007

Prolonged Survival in Leukemia Models Demonstrated

ROCKVILLE, Md., Dec. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results in preclinical leukemia models for its antimitotic agent, ENMD-1198, in combination with vincristine. The data were presented by EntreMed collaborator, Dr. Maria Kavallaris, at the American Society of Hematology Annual Meeting being held December 8-11, 2007 in Atlanta, Georgia.

(Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

Data presented demonstrate that ENMD-1198, administered as a single agent, is effective in significantly delaying the growth of leukemia xenografts in vivo. Combination studies with ENMD-1198 and another microtubule targeting agent commonly used in the treatment of leukemias, vincristine, demonstrate synergistic effects on leukemia cells in vitro and tolerability of doses that prolonged survival in leukemia xenograft models.

ENMD-1198, a new chemical entity (NCE) derived from 2-methoxyestradiol (2ME2), was designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1alpha. In prior preclinical studies, ENMD-1198, an orally active antimitotic agent, leads to arrest of cell division and apoptosis in tumor cells. ENMD-1198 also exerts antiangiogenic activity that further contributes to its overall antitumor effects.

Mark R. Bray, Ph.D., EntreMed Vice President, Research, commented on the results, "We continue to be encouraged by the potent preclinical antitumor activity of ENMD-1198 as a single agent and in combination with other chemotherapeutics. The observation that two active microtubule agents can be combined to produce synergistic activity at tolerated doses is quite encouraging. ENMD-1198 is currently being evaluated in a Phase 1 study in refractory solid tumor patients and we anticipate commencement of Phase 2 clinical studies in 2008."

To view the poster presentation, visit the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
7. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
8. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
9. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
10. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
11. Retirement Living TV Presents Sex, Drugs and Rock N Roll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology: